131 related articles for article (PubMed ID: 1904314)
1. Hexamethylmelamine: activity in lymphoma and other tumors.
Macdonald JS
Cancer Treat Rev; 1991 Mar; 18 Suppl A():99-102. PubMed ID: 1904314
[TBL] [Abstract][Full Text] [Related]
2. Hexamethylmelamine use in the treatment of metastatic breast cancer.
Henderson IC; Shapiro CL
Cancer Treat Rev; 1991 Mar; 18 Suppl A():91-8. PubMed ID: 1904313
[No Abstract] [Full Text] [Related]
3. The role of hexamethylmelamine in the management of ovarian cancer.
Schein PS; Scheffler B; McCulloch W
Cancer Treat Rev; 1991 Mar; 18 Suppl A():67-75. PubMed ID: 1904311
[TBL] [Abstract][Full Text] [Related]
4. Hexamethylmelamine (altretamine) in small cell lung cancer (SCLC).
Comis RL
Cancer Treat Rev; 1991 Mar; 18 Suppl A():85-90. PubMed ID: 1646071
[No Abstract] [Full Text] [Related]
5. Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
Legha SS; Slavik M; Carter SK
Cancer; 1976 Jul; 38(1):27-35. PubMed ID: 820422
[TBL] [Abstract][Full Text] [Related]
6. Hexamethylmelamine (altretamine): early National Cancer Institute trials.
Young RC
Cancer Treat Rev; 1991 Mar; 18 Suppl A():31-5. PubMed ID: 1904307
[No Abstract] [Full Text] [Related]
7. Hexamethylmelamine: a critical review of an active drug.
Foster BJ; Harding BJ; Leyland-Jones B; Hoth D
Cancer Treat Rev; 1986 Dec; 13(4):197-217. PubMed ID: 3102057
[TBL] [Abstract][Full Text] [Related]
8. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study.
Gagliano RG; Stephens RL; Costanzi JJ; Oishi N; Stuckey WJ; Grozea PN; Frank J; Crawford ED
Cancer Treat Rep; 1984; 68(7-8):1025-6. PubMed ID: 6430559
[No Abstract] [Full Text] [Related]
10. Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
Seski JC; Edwards CL; Copeland LJ; Gershenson DM
Obstet Gynecol; 1981 Sep; 58(3):361-3. PubMed ID: 6791063
[TBL] [Abstract][Full Text] [Related]
11. Therapy of small cell carcinoma of the lung with hexamethylmelamine.
Huang MN; Takita H; Catane H; Yee Chen T
Oncology; 1978; 35(1):29-32. PubMed ID: 203884
[TBL] [Abstract][Full Text] [Related]
12. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M; Blessing JA; Moore D; Ball H; Lentz SS
Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
[TBL] [Abstract][Full Text] [Related]
13. Hexamethylmelamine, vincristine, and methotrexate chemotherapy in advanced neoplasms.
Longacre D; Donavan M; Paladine W; Cunningham T; Sponzo R
Cancer Treat Rep; 1977 Aug; 61(5):919-22. PubMed ID: 408004
[No Abstract] [Full Text] [Related]
14. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.
Hartenbach EM; Harris LS; Bailey HH; Grosen EA; Larrison E; Chen D; Twiggs LB; Schink JC
Cancer J Sci Am; 1999; 5(6):348-55. PubMed ID: 10606476
[TBL] [Abstract][Full Text] [Related]
16. Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer.
Wharton JT
Cancer Treat Rev; 1991 Mar; 18 Suppl A():15-21. PubMed ID: 1904304
[No Abstract] [Full Text] [Related]
17. Phase II study of vindesine, cisplatin, and hexamethylmelamine (VCH) in small cell carcinoma of the lung.
Daugaard G; Hansen HH; Rørth M
Cancer Treat Rep; 1984 Sep; 68(9):1179-81. PubMed ID: 6090016
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and antitumor activity of hexamethylmelamine and its N-demethylated metabolites in mice with transplantable tumors.
Lake LM; Grunden EE; Johnson BM
Cancer Res; 1975 Oct; 35(10):2858-63. PubMed ID: 808270
[TBL] [Abstract][Full Text] [Related]
19. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group.
Wiernik PH; Yeap B; Vogl SE; Kaplan BH; Comis RL; Falkson G; Davis TE; Fazzini E; Cheuvart B; Horton J
Cancer Invest; 1992; 10(1):1-9. PubMed ID: 1735009
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer.
Hauge MD; Long HJ; Hartmann LC; Edmonson JH; Webb MJ; Su J
Invest New Drugs; 1992 Nov; 10(4):299-301. PubMed ID: 1487403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
